If you made any changes in Pure these will be visible here soon.
Filter
Literature review

Search results

  • 2016

    No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

    Hollestelle, A., van der Baan, F. H., Berchuck, A., Johnatty, S. E., Aben, K. K., Agnarsson, B. A., Aittomäki, K., Alducci, E., Andrulis, I. L., Anton-Culver, H., Antonenkova, N. N., Antoniou, A. C., Apicella, C., Arndt, V., Arnold, N., Arun, B. K., Arver, B., Ashworth, A., Baglietto, L., Balleine, R. & 32 others, Bandera, E. V., Barrowdale, D., Bean, Y. T., Beckmann, L., Beckmann, M. W., Benitez, J., Berger, A., Berger, R., Beuselinck, B., Bisogna, M., Bjorge, L., Blomqvist, C., Bogdanova, N. V., Bojesen, A., Bojesen, S. E., Bolla, M. K., Bonanni, B., Brand, J. S., Brauch, H., Brenner, H., Brinton, L., Brooks-Wilson, A., Bruinsma, F., Brunet, J., Brüning, T., Budzilowska, A., Bunker, C. H., Burwinkel, B., Butzow, R., Figueroa, J., Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2 & Tomlinson, I., May 2016, In: Gynecologic Oncology. 141, 2, p. 386-401 16 p.

    Research output: Contribution to journalLiterature reviewpeer-review